key: cord-0781029-s7gulp49 authors: Yan, Huadong; Vijay, Amrita; Jiang, Fanrong; Zheng, Nanhong; Hu, Yaoren; Ye, Honghua; Ollivere, Benjamin; Cai, Ting; Valdes, Ana M; Aithal, Guruprasad P. title: Serum glucose, lactate dehydrogenase and hypertension are mediators of the effect of body mass index on severity of COVID‐19 date: 2021-02-16 journal: Endocrinol Diabetes Metab DOI: 10.1002/edm2.215 sha: 3af1651795c321648d56f2e557f168727dedb6b7 doc_id: 781029 cord_uid: s7gulp49 BACKGROUND: COVID‐19 has a broad clinical spectrum. We investigated the role of serum markers measured on admission on severity as assessed at discharge and investigated those which relate to the effect of BMI on severity. METHODS: Clinical and laboratory data from 610 COVID‐19 cases hospitalized in the province of Zheijang, China were investigated as risk factors for severe COVID‐19 (assessed by respiratory distress) compared to mild or common forms using logistic regression methods. Biochemical markers were correlated with severity using spearman correlations, and a ROC analysis was used to determine the individual contribution of each of the biochemical markers on severity. We carried out formal mediation analyses to investigate the extent of the effect of body mass index (BMI) on COVID‐19 severity mediated by hypertension, glycemia, Lactose Dehydrogenase (LDH) at the time of hospitalization and C‐Reactive Protein levels (CRP), in units of standard deviations. RESULTS: The individual markers measured on admission contributing most strongly to prediction of COVID‐19 severity as assessed at discharge were LDH, CRP and glucose. The proportion of the effect of BMI on severity of COVID‐19 mediated by CRP, glycemia or hypertension, we find that glucose mediated 79% (p < .0001), LDH mediated 78% (p < .0001), hypertension mediated 66% (p < .0001); however, only 44% (p < .005) was mediated by systemic inflammation (CRP). CONCLUSION: Our data indicate that a larger proportion of the effect of BMI on severity of COVID‐19 is mediated by glycemia and LDH levels whereas less than half of it is mediated by systemic inflammation. The clinical spectrum of SARS-CoV-2 infection appears to be wide, encompassing asymptomatic infection, mild upper respiratory tract illness with cough, fever and fatigue to more severe viral pneumonia with a risk of consequent respiratory failure and death. Risk factors associated with symptomatic disease requiring hospitalization are uncertain and factors that influence the risk of developing severe disease remain incompletely understood. Age has been consistently associated with increased mortality 1 ; type 2 diabetes and hypertension, two most prevalent comorbidities in hospitalized patients have been also associated with severe manifestations. [2] [3] [4] Recent data coming from the US and Western Europe show that being overweight or obese is a significant risk factor associated with hospitalization, 5 requirement to mechanical ventilation 6, 7 and in-hospital mortality from COVID-19. 1 A number of mechanisms may underlie association of body mass index (BMI) and pneumonia including increased airway resistance and reduced respiratory muscle strength, lung volumes, and gas exchange. 8 However, it has emerged that patients with high BMI are at greater risk of death from COVID-19 than patients with asthma. 1 This suggests that the mechanisms by which SARS-Cov2 develops into a severe form of COVID-19 may be directly related to metabolic pathways that are specifically dysregulated in obese or overweight individuals. Obesity is also a key risk factor for type 2 diabetes, hypertension and cardiovascular disease all of which have been associated with COVID-19. Furthermore, metabolic impairment characterized by insulin resistance, hyperglycaemia and dyslipidaemia may remain unrecognized in substantial proportion of the population. 9 Evaluating of these parameters is important to risk stratify patients with COVID-19. 10 The objective of this study was to identify risk factors for symptomatic COVID-19 and the development of its severe/critical form using a multicentre retrospective cohort of 610 patients with COVID- 19 The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The local ethics committees of all hospitals approved the retrospective study of cohorts COVID-19. The requirement for written consent was waived due to the retrospective and anonymous nature of this study. The severity of the disease was classified according to the Guidelines for the Diagnosis and Treatment of New Coronavirus Pneumonia (fifth edition) 12 and categorized into 4 groups as described previously. 13 In brief, patients were classified into the fol- Individual demographic and clinical features were tested for association with the 4-point scale of severity described above using a Spearman's correlation. Those variables that were significantly associated with the categorical measure of severity were then included in a LASSO logistic regression to select specific features to test as predictors of severe outcome (grade 3 or 4 of the categorical scale) vs less severe outcome (grade 1 or 2). Clinical laboratory test results, including SARS-CoV-2 RNA detection results, biochemical indices, blood routine results, were Categorical variables were expressed as frequency and percentages. Continuous variables were expressed as mean and standard deviations. Logistic regressions were carried out either unadjusted or adjusting for covariates as indicated in the table legends. p < .05 was considered statistically significant. To formally assess the contribution of CRP, LDH, glycemia and hypertension to the association between BMI and disease severity, we conducted mediation analysis using the 'mediation' package in R version 3.6.1 where we considered the various clinical traits as mediator for the causal effect of BMI on severity. Analyses were carried out using R version 3.6.1. p < .05 was considered statistically significant. The selection of the study population was carried based on a previously published protocol. 13 We proceeded to investigate the biochemical and clinical factors that correlate with the disease severity. The demographic, clinical presentation features and biochemical markers in each of the four severity categories are shown in Table 1 . We found that BMI greater than 23 kg/m 2 was strongly associated with a more severe form of the disease, but BMI below 23 kg/m 2 was not. We also found significant associations with male sex and older age. In terms of the biochemical measures, we found glucose and LDH having the most dramatic effect on severity compared to others. The presence of hypertension was significantly associated with severity, but type 2 diabetes was not. We further ranked the biochemical markers correlated with severity and put them side by side with some of the demographic characteristics in terms of how much they can explain severity on a ROC analysis including each variable independently ( Figure 2 ). We found that levels of LDH, CRP and glucose on admission were each individually able to predict 75% or more of COVID-19 severity. Furthermore, we found that LDH was a greater predictor of severity we also explored the mediatory effect of hypertension, given its strong links to metabolic syndrome and found that it mediated 66% (p < .001) of the effect of BMI on severity as shown in Table 2 . We also carried a regression analysis of severity with glucose and BMI and found significant associations for glucose (beta = 0.25, 0.89-1.53 95% CI, p=<0.001) and for BMI (beta = 0.14, 0.33-1.25 95%CI, p = .001). Furthermore, a regression of glucose on BMI was also found to be significant (beta = 0.14, 0.77-0.27 95% CI, p = .001). TA B L E 1 Association between demographics, biochemical measures, comorbidities and severity. odds ratios were derived by logistic regression severe (severe + critical) vs not severe (mild + common Finally, although diabetes was not a strong risk factor for severity, it could be that the high levels of glucose seen to be predictive of severity may be only seen in diabetic patients. Therefore, we further investigated its effect in patients with and without type 2 diabetes and in the overweight/obese (BMI > 23 kg/m 2 ) and normal weight (BMI < 23 kg/m 2 ) categories. We found that glucose was Note: Models were built in to assess the effect of association between overweight/obese (BMI > 23) and severity mediated by clinical traits. The effect observed is described in the 'effect' column where: Null, corresponds to no association observed between high BMI ad severity mediated by the traits of interest. Partial, the association between the high BMI and severity is partially mediated by the clinical trait of interest. Direct, the association between high BMI and severity is fully mediated by the clinical trait of interest. significantly associated with severity in patients with and without type 2 diabetes (Figure 3) . Similarly, the association of glucose with severity was significant in the overweight/obese category compared to the normal weight category. Furthermore, we found that CRP, a common marker of systemic inflammation, was significantly associated with severity in the presence or absence of type 2 diabetes and amongst normal and overweight categories as shown in Figure 3 . A similar pattern was seen with regards to LDH levels. We have carried out formal mediation analyses to investigate the extent to which the effect of body mass index (BMI) on COVID-19 severity is mediated by glycaemia, LDH, CRP and hypertension. Both serum glucose and CRP have been functionally linked to higher BMI in the general population. [14] [15] [16] Obesity-induced meta-inflammation is associated with systemic increases in circulating inflammatory cytokines and acute phase proteins such as CRP and recruitment of leucocytes to inflamed tissues. 17 Obesity has also been shown to impair immune response to influenza virus. 18 When we investigated the proportion of the effect of BMI mediated by these two factors, we found that a higher proportion of the effect of BMI on COVID-19 severity is mediated by glycaemia than by CRP. Our mediation analysis also finds that the effect of BMI is also mediated by hypertension more so than by CRP (Figure 3 ). Previous meta-regression analysis has shown in African American and white individuals under the age of 50 with a median BMI of 29 found that hypertension and diabetes did not affect the relationship between obesity and severity. 19 However, in our study population, half of the patients were 50 or older with a median BMI of 23.9 and only 4 individuals in our patient cohort had a BMI > 35. It is therefore possible that in younger and is unlikely to bias our results as there were not any sites with significantly larger numbers of severe cases. In conclusion, we find that baseline patient-related and laboratory parameters in combination can be used to risk stratify COVID- The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest related to this manuscript. The data that support the findings of this study are available from the corresponding author, upon reasonable request. Amrita Vijay https://orcid.org/0000-0002-9595-5680 Factors associated with COVID-19-related death using OpenSAFELY Clinical characteristics of coronavirus disease 2019 in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease High prevalence of obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission Obesity and respiratory diseases Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans Obesity and impaired metabolic health in patients with COVID-19 Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies National Health Commission of the people's Republic of China.The Guidelines for the Diagnosis and Treatment of New Coronavirus Pneumonia Role of drugs used for chronic disease management on susceptibility and severity of COVID-19: a large case-control study Metabolic flexibility in health and disease Obesity and C-reactive protein in various populations: a systematic review and meta-analysis Effect of plant-based diets on obesity-related inflammatory profiles: a systematic review and meta-analysis of intervention trials Inflammatory links between obesity and metabolic disease Obesity impairs the adaptive immune response to influenza virus Severe obesity as an independent risk factor for COVID-19 mortality in hospitalized patients younger than 50 Stress hyperglycemia: an essential survival response! Crit Care The clinical characteristics and outcomes of diabetes mellitus and secondary hyperglycaemia patients with coronavirus disease 2019: a single-center, retrospective, observational study in Wuhan The effect of short-term hyperglycemia on the innate immune system The immunologic Warburg effect: Evidence and therapeutic opportunities in autoimmunity Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes Diet and glycaemia: the markers and their meaning. A report of the Unilever Nutrition Workshop Predicting personal metabolic responses to food using multi-omics machine learning in over 1000 twins and singletons from the UK and US: the PREDICT I Study (OR31-01-19) Personalized nutrition by prediction of glycemic responses Prediabetes: a high-risk state for diabetes development ing -ill-healt h-and-prema ture-death -in-black -asian -and-other -minor ity-ethni c-group s-pdf-19963 61299141. Accessed: 21.08.2020. How to cite this article